Mirum Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Great, good morning, everyone. Welcome. I'm Jess Fye, senior biotech analyst at JPMorgan. And we're continuing the 42nd Annual Healthcare Conference today with Mirum.
I'm joined on stage by the company's CEO, Chris Peetz. He's going to give a presentation on the business and then we're going to go into Q&A. If you want to ask a question in the room, you can raise your hands, and we'll bring you a microphone or you can submit them via the portal. So with that, let me pass over to Chris.
Thanks, Jess, and thanks for hosting us here today. Really excited to give you an update on Mirum, and introduction for those not familiar. And quick note that we'll be making forward-looking statements in the presentation, so I refer you to our SEC filings for a more complete disclosure of risk factors.
Mirum is a commercial rare disease company with a leading position in pediatric hepatology, took dramatic steps forward in building out both the operating scale
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
